PCA3 messenger RNA species in benign and malignant prostate tissues
First Claim
Patent Images
1. A method of determining the malignancy status of prostate cells contained in a sample undergoing testing, said method comprising:
- (a) amplifying a first PCA3 nucleic acid across nucleotide positions 26 and 255 of SEQ ID NO;
1 and a second PCA3 nucleic acid across nucleotide positions 26 and 27 of SEQ ID NO;
2 from mRNAs obtained from prostate cells contained in said sample if such first and/or second nucleic acids are present, whereby said first and second PCA3 nucleic acids are synthesized in relative abundance dependent on the malignant and non-malignant status of the prostate cells,wherein the amplification of said first PCA3 nucleic acid results from amplification of a first PCA3 mRNA that comprises an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO;
1, andwherein the amplification of said second PCA3 nucleic acid results from amplification of a second PCA3 mRNA that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence; and
(b)i) determining a malignant status of the prostate cells in said sample by detecting a higher level of said second PCA3 nucleic acid as compared to said first PCA3 nucleic acid;
orii) determining a non-malignant status of the prostate cells in said sample by detecting a higher level of said first PCA3 nucleic acid as compared to said second nucleic acid;
thereby determining the malignancy status of said prostate cells in said sample.
10 Assignments
0 Petitions
Accused Products
Abstract
This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
62 Citations
16 Claims
-
1. A method of determining the malignancy status of prostate cells contained in a sample undergoing testing, said method comprising:
-
(a) amplifying a first PCA3 nucleic acid across nucleotide positions 26 and 255 of SEQ ID NO;
1 and a second PCA3 nucleic acid across nucleotide positions 26 and 27 of SEQ ID NO;
2 from mRNAs obtained from prostate cells contained in said sample if such first and/or second nucleic acids are present, whereby said first and second PCA3 nucleic acids are synthesized in relative abundance dependent on the malignant and non-malignant status of the prostate cells,wherein the amplification of said first PCA3 nucleic acid results from amplification of a first PCA3 mRNA that comprises an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO;
1, andwherein the amplification of said second PCA3 nucleic acid results from amplification of a second PCA3 mRNA that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence; and (b) i) determining a malignant status of the prostate cells in said sample by detecting a higher level of said second PCA3 nucleic acid as compared to said first PCA3 nucleic acid;
orii) determining a non-malignant status of the prostate cells in said sample by detecting a higher level of said first PCA3 nucleic acid as compared to said second nucleic acid;
thereby determining the malignancy status of said prostate cells in said sample. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
Specification